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Commentary & View
What Is the Storage Effect, Why Should It
Occur in Cancers, and How Can It Inform
Cancer Therapy?
Anna K. Miller, PhD1 , Joel S. Brown, PhD1, David Basanta, PhD1, and
Nancy Huntly, PhD2
Abstract
Intratumor heterogeneity is a feature of cancer that is associated with progression, treatment resistance, and recurrence.
However, the mechanisms that allow diverse cancer cell lineages to coexist remain poorly understood. The storage effect is a
coexistence mechanism that has been proposed to explain the diversity of a variety of ecological communities, including coral reef
fish, plankton, and desert annual plants. Three ingredients are required for there to be a storage effect: (1) temporal variability in
the environment, (2) buffered population growth, and (3) species-specific environmental responses. In this article, we argue that
these conditions are observed in cancers and that it is likely that the storage effect contributes to intratumor diversity. Data that
show the temporal variation within the tumor microenvironment are needed to quantify how cancer cells respond to fluctuations
in the tumor microenvironment and what impact this has on interactions among cancer cell types. The presence of a storage effect
within a patient’s tumors could have a substantial impact on how we understand and treat cancer.
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Introduction
Ecosystems in nature include coexisting species that compete for
space, resources, and safety from predators.1-4 Similarly, tumors
exhibit microenvironmental heterogeneity that contains coexist-
ing cancer cell types that experience variations in nutrients, toxic
metabolites, and diverse types of normal cells.5 In nature,
mechanisms of coexistence can explain the diversity of species
within a community. Typical mechanisms include food-safety
trade-offs (one species is the better competitor, while the other is
better at avoiding predation), diet separation (each species has a
subset of resources on which it is the more successful consumer),
habitat selection (each species has a habitat within which it is
more successful), and competition-colonization trade-offs (one
species slowly outcompetes the other at a given spot, while the
other is more successful at dispersing to unoccupied spots). Sim-
ilar mechanisms likely explain some of the diversity of cancer
cell types within and among a patient’s tumors.6
Long underappreciated in ecology was a mechanism of
coexistence now known as the storage effect.7-11 Three ingre-
dients can promote the coexistence of species by the storage
effect: (1) temporal variability in environmental conditions that
include periods favorable and unfavorable for survival and
reproduction (we shall refer to these as good and bad), (2) the
presence of 2 life-history states within each species (one
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conducive to proliferation during good periods, the other con-
ducive to survival during bad periods), and (3) differences in
how species perceive and invest effort to grow, or do not, in
good and bad periods, reflecting some underlying trade-offs
and adaptation to somewhat different environmental
conditions.
Here, we posit that the storage effect may promote the coex-
istence of at least some cancer cell types within the tumors of
some or many different cancers. To demonstrate the plausibil-
ity of the storage effect, we discuss how, as in ecosystems in
nature, conditions (1) and (2) are universal properties of most
tumor microenvironments. Next, we discuss why there may be
trade-offs in the way cancer cells experience good and bad
periods. We then discuss how the storage effect manifests in
nature, followed by a simple mathematical model for cancer
tumor cells, illustrating how the storage effect works. We con-
clude with a discussion of how knowledge of the presence of a
storage effect in a patient’s disease might inform therapies.
Temporal Variation in Nature and the Tumor
Microenvironment
Very few, if any, ecological communities experience temporally
constant environments. Migratory birds escape the harsh winter
conditions of higher latitudes by migrating to destinations closer
to the equator. Deciduous trees lose their leaves during dry and/
or cold seasons. Year-to-year variation in temperature and pre-
cipitation may portend droughts or floods and hot spells and cold
snaps. Fire, disease, or pestilence occurs episodically within
ecosystems. A beaver damming a stream can raise water tables,
drown surrounding terrestrial vegetation, and create a wetland.
This wetland can revert when the beaver dam breaks or decays.
Virtually, all living organisms experience predictable and
unpredictable variability in environmental conditions that influ-
ence growth, reproduction, and survivorship.
Like natural ecosystems, cancer cells inhabiting a tumor
microenvironment experience both regular and irregular tem-
poral fluctuations. Blood flow changes due to unstable vascu-
lature on time scales of minutes to hours.12 This instability
arises as cancer cells adapt to local hypoxic conditions by
recruiting new blood vessels, which enable the delivery of
nutrients and the removal of toxic metabolites so that cancer
cells can survive when nutrients are low. However, as cancer
cells induce the growth of new blood vessels, the vascular
network becomes more irregular and disorganized, leading to
unpredictable spatial and temporal variations in blood flow.13
Consequently, transient changes in perfusion lead to cycling
hypoxia. Local fluctuations between hypoxia and reoxygena-
tion affect cells adjacent to the poorly perfused blood vessels.
This is in contrast to chronic hypoxia, which affects cells far
away from vessels due to limited diffusion. Cycling hypoxia is
associated with an increase in cell migration, metastatic poten-
tial, and resistance to treatments compared to chronic
hypoxia.14
While changing patterns of blood flow likely create the
greatest source of temporal variability in oxygen, pH, immune
infiltration, nutrients, and toxins, the architecture of cells
within and around a tumor microenvironment also may change
temporally. The rate of diffusion of nutrients (such as glucose
and glutamine) toward a neighborhood of cancer cells and the
diffusion of metabolites away (such as lactate, free-oxygen
radicals, and pyruvate) may vary temporally as other neighbor-
hoods of cancer cells block or unblock intracellular channels,
as immune cells move in or out of an area, and as fibroblasts
change extracellular matrices and/or the secretion of growth
factors. Regardless of its source or regularity, coexisting cancer
cells experience considerable temporal variability in opportu-
nities and hazards that likely create good and bad periods in
terms of their proliferation and survival rates, setting the poten-
tial for the storage effect to promote diversity of cancer cells
within tumors.
Proliferative and Nonproliferative
Life-History States in Nature and Cancer
In response to fluctuations that generate good and bad periods,
many organisms have evolved different life-history states: one
that is best at exploiting the good times and the other best at
surviving through the bad times. Many single-celled protists
have a proliferative state that allows the cell to feed, move, and
proliferate.15 This state, however, may not be able to survive
bad periods when their pool of water dries up or the environ-
ment offers only toxins and no nutrients. Such protists also
have an encysted state. This state, although unable to prolifer-
ate, is highly resistant to desiccation, toxins, and nutrient depri-
vation. This state may be the only way the protist survives
through bad periods. Having a fraction of the protist population
in an encysted state means that some opportunities are lost
during good periods, but survival is ensured during the bad.
Baker’s yeast is a classic example. The dry packet of encysted
yeast can survive for years without an opportunity for growth
and reproduction. Upon activation and favorable conditions,
this yeast enters a feeding and proliferative state. Among spe-
cies in nature, “quiescence” or “dormancy” refers to a range of
cellular or organismal states characterized by slowed metabo-
lism and relatively high resistance to hardships from their sur-
rounding environment.16-21
In cancer, cells that are reversibly arrested in the G0 phase
of the cell cycle are referred to as quiescent, whereas “cell
dormancy” typically refers to a long-term quiescence.22 Many
cancer cells respond to hypoxia by becoming quiescent and
upregulating autophagy to survive lower levels of nutrients and
oxygen.13 Cancer cells may survive harsh environments (eg,
hypoxia, low pH, toxins) by forming poly-aneuploid cancer
cells (also referred to in the literature as polyploid giant cancer
cells), a population of reversibly quiescent cells that form rap-
idly (within 72 hours) in response to environmental stress and
later divide asymmetrically to repopulate a tumor with cells of
normal ploidy that have increased resistance to chemother-
apy.23,24 In their nonproliferative state, dormant or quiescent
tumor cells are able to evade treatments that preferentially
target highly proliferative cells. After treatment, these cells can
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resume proliferation, which can result in tumor growth and
relapse. Quiescent states are ubiquitous in cancer and can be
associated with metastasis and relapse of cancerous growth.25
As such, dormancy and quiescence challenge our ability to
treat, control, or moderate cancer.
Some readers may see similarities between cancer stem cells
(CSCs) and our description of quiescent and dormant cancer
cells. The similarity does manifest when CSC refers to a subset
of heterogeneous cancer cells that exhibit plasticity, drug resis-
tance, and tumor-initiating capability. But, CSC concepts
diverge from our use of quiescence and dormancy when CSCs
are seen as a small population of undifferentiated, self-
renewing cells that give rise to and sustain a population of
terminally differentiated cells. Once fully differentiated, these
cells are viewed as being nonproliferative even as they make up
the bulk of the tumor. Cancer stem cells can undergo either
symmetric or asymmetric cell division, where the former
increases the CSC population and the latter promotes the dif-
ferentiated population. For the storage effect, the proliferative
state is vulnerable to harsh conditions while the nonprolifera-
tive quiescent state is not. Each state can phenotypically shift
into the other.
In nature, quiescent and resistant states can have a powerful
effect. They can allow populations to survive despite exposure
to conditions that limit or preclude population growth. They
can buffer populations against variation in favorability for
growth on many time scales, including seasonal, annual, and
multiannual; they can contribute to more diverse communities
than would exist without them.9,10,26-28 Given how common
dormancy/quiescence is in cancer, we expect to find similar
ecological effects of these life-history stages for the cancer
ecosystem. Quiescent or dormant states could maintain diverse
cancer phenotypes that may proliferate, coexist, or displace
each other over the course of time within the patient. For
instance, disseminated cancer cells that stay dormant, some-
times for many years, and then reemerge as metabolically
active cells that proliferate, often leading to the death of
patients. These emergent metastases appear to result from
enhanced cell lineage persistence through dormancy.23-25,29,30
The movement of cells into and out of dormancy, as the envi-
ronment around them changes, could affect what clones co-
occur in a tumor or in a patient by changing the ways in which
cell–cell interactions such as competition play out at the level
of populations of different cell types. The presence of quiescent
and dormant, resistant states of cancer cells sets the potential
for the storage effect to promote the diversity of cancer cells
within tumors. These possibilities have clear relevance for can-
cer control.
Evidence for Population-Specific Behaviors
and Trade-Offs in the Way Cancer Cells
Experience Good and Bad Times
As in nature, where a year with plentiful but not excessive
water would be expected to be generally a good year for
vegetation, cancer cells also would share many environmental
needs and so experience good and bad times in part together.
However, as with plants that differ in tolerance to low water
availability or high temperatures, cancer cells differ in their
sensitivities to hypoxia, low pH, immune infiltration, the
absence of growth factors, and the stromal (created by normal
cells) architecture of their microenvironment, generating
potential for trade-offs that make some periods better for some
cell clones and others better for other clones. The heterogeneity
of cancer cells in many features, including their proliferative
potential, hormone receptor expression, immunogenicity, sen-
sitivity to drugs, motility, and angiogenic potential,31 enables
cancer cells to have population-specific environmental
responses, an essential component of the storage effect. For
example, in stage 2 invasive breast cancers, cells on the tumor
edge tend to have an acid-producing invasive, proliferative
phenotype, whereas those in the hypoxic tumor core have a
less proliferative phenotype.32 Tumors also have metabolic
heterogeneity in the form of acid-resistant or glycolytic pheno-
types.33 Mathematical models of cancer evolution suggest that
high nutrient variability (cycling hypoxia) gives a competitive
advantage to cancer cells that have a higher rate of phenotypic
transition, which promotes high levels of phenotypic
heterogeneity.34
Cancer cells, and even normal cells, have a wide range of
behaviors associated with entering and exiting from nonproli-
ferative states, which provide the buffering life-history stage
that enables a storage effect. Cancer cells may remain in these
states for times ranging from the very short (1 to several days)
to the very long (decades, as observed for emergence of meta-
static cancer growth after years of healthy remission).25,35 In
fibroblasts, cells move deeper into quiescence following longer
durations of serum starvation or contact inhibition and require a
stronger growth stimulation to exit quiescence compared to
cells in shallow quiescence.36 Interactions between cancer cells
and the tumor microenvironment can promote quiescence or
dormancy. For example, bone-lining osteoblasts and endothe-
lial cells on stable vasculature secrete factors that keep disse-
minated tumor cells dormant,37 and adhesion of multiple
myeloma cells to extracellular matrix components such as
fibronectin leads to quiescence.38
The time of exit from quiescence can vary within a clonal
population, even when cultured in the same growth condi-
tions.39 Dormant cells awaken due to environmental changes.
Bone is highly dynamic, undergoing constant remodeling,
which can reawaken dormant cancer cells.40 The growth of
new blood vessels provokes sufficient change to the microen-
vironment to reactivate breast cancer cells.41,42 Age-related
inflammation promotes the outgrowth of dormant cells in pan-
creatic ductal adenocarcinoma liver metastases.43 Poly-
aneuploid cancer cells emerge from quiescence after removal
of chemotherapy, and they do so after a range of quiescence
durations (Sarah Amend, PhD, email communication, February
2020). Drug resistance is associated with a heterogeneous pop-
ulation of nonproliferative cells, including drug-tolerant pers-
isters, therapy-induced senescent cells, hypoxic drug-resistant,
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and disseminated tumor cells. These populations differ in their
propensities to remain in or exit the growth-arrested state.22
A Simple Model of the Storage Effect in
Cancer
Mathematical models have been useful to understand cancer
biology and to help test what treatment strategies might
improve patient outcomes over the standard of care. Many
model types have been used, including game theory mod-
els,44-51 agent-based models,33,52-57 and Lotka-Volterra-type
dynamical models that consider cancer clonal cells as interact-
ing populations.58,59 So far, very few of these models consider
variation in the environment of cancer cells in time. It is unsur-
prising that temporal variation in the tumor environment has
had little attention in dynamical models. This was long the case
in models of natural ecosystems, and the data available for
cancer tend to be static snapshots of a tumor. Radiographic and
histologic images show cancer at a point in time. Although they
reveal, and provide data for, modeling spatial heterogeneity in
cancer, they do not capture or inform the potential variation in
time that small-scale physiological studies indicate is there as
well.12,14,60
Stochastic dynamic models of interacting populations of
cancer cells are a straightforward way to incorporate temporal
environmental variation and are the class of models that have
primarily been used to develop an understanding of the storage
effect. The simple Lotka-Volterra-type population models so
far used to study cancer are not sufficient to capture coexis-
tence mechanisms such as the storage effect because they do
not incorporate a nonproliferative life-history state nor do they
incorporate species-specific demographic responses to a vary-
ing environment.3,61,62 Variation in the environment can be
proxied as stochastic variation in demographic parameters,
such as entry to and exit from quiescence and rates of growth,
reproduction, or survival of cancer cells.
To show how coexistence can occur via the storage effect,
we construct a simple discrete-time stochastic model that
includes 2 species, each with 2 life-history stages (proliferative
and quiescent) and stochastic variation in good and bad
periods.
Illustrating the Storage Effect
The plausibility of the storage effect promoting the coexistence
of different cell types within a tumor microenvironment
emerges from (1) temporal variability in blood flow, immune
infiltration, stromal architecture, and physical conditions and
(2) the widespread occurrence of cell arrest, quiescence, and/or
dormancy that allows cancer cells to exist in 2 states—prolif-
erative and nonproliferative. Coexistence can occur if there is a
trade-off in how 2 cell types experience good and bad periods.
To illustrate how storage effects can work, we propose a
simple model that aims to keep assumptions to a minimum
while containing the essential elements. We imagine that each
cancer cell type has 2 stages: an arrested state and a
proliferative state. A fraction of cells, y, leave the arrested state
during each period. Those that enter the proliferative state have
a mortality rate that depends on whether it is during a “good” or
“bad” period. These periods could represent a microenviron-
ment of a tumor where fluctuations in blood flow, hypoxia,
and/or growth factors contribute to times of plenty and times
of famine. Upon emerging from the arrested state, cells suc-
cessfully survive to proliferate at fraction s. Let sg >> sb be
these survival rates during good and bad periods, respectively.
The biology here is that if a cell attempts to be proliferative,
it may lack key resources even as the cell commits to cell
division. The consequence is cell mortality that would not have
happened had the cell remained in an arrested state. For exam-
ple, providing estrogen to breast cancer cells that otherwise
have no other nutrients can cause mortality, as cells are tricked
into trying to proliferate (Robert Gatenby, MD, email commu-
nication, February 2020). Those cells that survive produce a
maximum number of daughter cells, f, that declines with com-
petition from other cells in a proliferative state. We use a
Ricker model to describe the competition between proliferative
cells for resources. In the absence of competitors, a prolifera-
tive cell produces its maximum number of daughter cells; with
competitors, the production of daughter cells declines exponen-
tially with the density of other proliferative cells. We imagine
that f can take on a positive value that represents the expected
number of daughter cells that might accrue during a period
sufficiently long to permit 1 or more rounds of cell division.
At the end of the period, daughter cells enter the pool of cells in
an arrested state.
Now let there be 2 cell types that are equal in all ways,
except that they do not always experience good and bad periods
in the same way. Although unlikely that 2 cell types would be
identical, this assumption allows us to illustrate coexistence
that only manifests because of the storage effect.
For cancer cell types, it is likely that what is good for one is,
in part, good for the other type. However, differences in nutri-
ent metabolism, sensitivity to growth factors, resistance to
hypoxia, the ability for immune evasion, and/or physical con-
ditions like pH mean that at times one cell type may experience
a bad period while the other a good period. Let q be the prob-
ability of a good period, and let 0  r  1 represent the degree
to which the 2 cell types experience good and bad periods
similarly. The term (1  r) then represents the probability that
the 2 cell types are experiencing the type of period indepen-
dently of each other. Thus, the probabilities of both experien-
cing good periods (pGG), both experiencing bad periods (pBB),
type 1 experiencing good and type 2 experiencing bad (pGB),
and vice versa (pBG) are given by:
pGG ¼ rqþ ð1 rÞq2
pBB ¼ rð1 qÞ þ ð1 rÞð1 qÞ2
pBG ¼ pGB ¼ ð1 rÞqð1 qÞ:
As they must, pGG, pBB, pBG, and pGB sum to 1.
Let xk(t) be the number of cells of type k in an arrested state
following time period t, where k¼ 1 or 2. The 2 species growth
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equations take on the following form:








where i, j ¼ g or b, and d is the mortality rate of cells in an
arrested state per period, and R scales the limits to growth by
representing some measure of resources available to cells that
are in a proliferative state.
The above model easily generates a coexistence via a storage
effect. This can be seen by showing how either species 1 or 2 can
invade a resident population of the other and that when together
they settle on a dynamic equilibrium but with more or less tem-
poral variation in the frequency of the 2 cell types within a
microenvironment (Figure 1). When averaged over many
microenvironments, the cell type frequencies might appear rel-
atively stable across time. If a storage effect is operating within a
tumor, then there may be surprisingly large fluctuations in cell
composition at the level of small neighborhoods of cancer cells.
The storage effect is not possible in the absence of an arrested
state. For y ¼ 1, the 2 cancer cell types exist as a stochastic
random walk with neither one having an advantage. An arrested
state buffers a cell type when it experiences a bad period, while
the other experiences a good period. Similarly, if r ¼ 1, then a
storage effect is not possible, as both cell types perceive good
and bad years identically. The 2 will simply experience a sto-
chastic random walk of population sizes with neither
experiencing an advantage when rare. Once r < 1 and y < 1, the
coexistence of cell types by the storage effect will happen, but
the strength of this will increase as r approaches 0. The advan-
tage that a cell type gains when it is rare (thus driving it to
increase in time at the expense of the other cell type) derives
from the occurrence of periods where the rare species experi-
ences a good and the resident cell type experiences a bad period,
giving the rare species opportunity to realize the high growth
potential of a good period without strong depression by compe-
tition. This is maximized when r¼ 0 and when q¼ 0.5 (good and
bad periods are equally likely). Furthermore, as a long-term
dynamic equilibrium, the average tumor burden increases as r
goes from 1 to 0; and as q goes from 0 to 1 (Figure 2).
How Might Consideration of the Storage
Effect Inform Cancer Therapy?
The existence of the storage effect contributing to diversity in
cancer would have consequences for clinical treatments. It is
recognized that intratumor and intertumor heterogeneity should
inform cancer therapy.63,64 For instance, intratumor heteroge-
neity is established as a marker for poor prognosis. Additional
therapeutic challenges arise if some of the diversity of cancer
cell types involve storage effect dynamics. The presence of a
storage effect presents a double challenge for therapy. First is
the task of targeting quiescent cells, and second is the challenge
of finding drugs effective on each or all of the cancer cell types.
Quiescence or dormancy now appears to be a major mechan-






















Total Species 1 Species 2
Figure 1. Invasion of resident population. Parameters: sg¼ 0.8, sb¼ 0.1, R¼ 100, d¼ 0.05, y¼ 0.2, f¼ 5, q¼ 0.4, r¼ 0.8, x1(0)¼ 100, x2(0)¼ 0,
x2(250) ¼ 1.
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metastases,23-25 so there is great interest in whether quiescent or
dormant cells can be targeted by therapies.65 This article argues
that we must also consider that there may be many coexisting
clonal lineages of cancer cells that differ in physiologies of their
nonproliferative and proliferative life-history states. If cancer cell
types coexist via the storage effect, then one is not targeting just a
single cell type, but a diversity of cell types with potentially
differing susceptibilities to therapy. Longitudinally monitoring
tumors and responses to therapy may require more frequent mag-
netic resonance imaging and other imaging techniques as nonin-
vasive tools for identifying and tracking different tumor habitats
based on vascularity, hypoxia, necrosis, and so on.66,67
Pseudo-Resistance
Heterogeneity in quiescence could obscure detection of resis-
tance to treatment through the phenomenon of pseudo-resis-
tance, a situation where an otherwise treatment-sensitive
population of cancer cells appears to be resistant. Pseudo-
resistance could result from temporal variation that selects
for cell lineages that maintain a high fraction of cells within a
quiescent state. Many cytotoxic chemotherapies target pro-
liferating cells that are actively dividing, and nonproliferative
cells may be insensitive to these therapies. Those parts of a
tumor that experience the greatest temporal variability may
have the greatest fraction of nonproliferative cells. In this case,
therapy may appear effective in eliminating tumor cells, but
continued efficacy may slow, as the remaining cancer clonal
populations have lower fractions of cells in a proliferative
state. The storage effect, by maintaining the coexistence of
cancer clones that vary in their propensity for remaining quies-
cent or arrested, could exacerbate pseudo-resistance.
With pseudo-resistance, continuing the same drug regimen
would continue to cull cancer cells as they emerge into a pro-
liferative state. However, the fraction of cancer cells killed with
each dosing would decline, generating the appearance of
declining tumor burden, but without entirely eradicating the
tumor. Prolonging the therapy may increase the likelihood of
true resistance emerging from the surviving cancer cells and
also may induce undue toxicities to the patient. The possibility
that pseudo-resistance might reflect a storage effect would sug-
gest novel therapeutic strategies. One approach might be to
maintain the ongoing therapy, but reduce dosage or make it
more intermittent (akin to maintenance therapy for patients in
remission). Frequent and accurate measures of tumor burden
might identify breakpoints in the rate of tumor burden decline,
which would indicate the presence of different clones with
different propensities to remain quiescent. A second therapeu-
tic approach could be to include in tandem an intervention
designed to amplify the rate at which cancer cells return from
quiescence into a proliferative state. It might also be useful to
begin with the first therapy and then add to it, rather than
replace it with, additional therapies; if possible, the second
therapy would be chosen for toxicity to quiescent cells.
0 0 1 154 366 506 600 664 707 735 752
0 0 1 142 356 496 590 657 702 732 752
0 0 1 145 352 485 582 650 697 730 752
0 0 1 140 342 480 572 642 690 727 752
0 0 1 136 333 470 564 636 686 724 752
0 0 1 134 325 462 558 627 679 722 752
0 0 1 131 321 454 548 621 675 719 752
0 0 1 122 317 443 539 614 671 715 752
0 0 1 124 303 439 533 606 664 713 752
0 0 1 122 302 429 523 599 660 710 752












Average Number of Arrested Cells
Figure 2. Average number of arrested cells as a function of q and r. Each combination represents an average of 10 simulations. Parameters: sg¼
0.8, sb ¼ 0.1, R ¼ 100, d ¼ 0.05, y ¼ 0.2, f ¼ 5, x1(0) ¼ 100, x2(0) ¼ 100, number of timesteps ¼ 104.
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The Storage Effect and Multidrug Therapies
The existence of a storage effect implies that additional data are
needed to predict tumor progression. Knowing to what extent
the variability that one sees in space also occurs in time at each
spot becomes a valuable and critical piece of information.
There is recognition of the need for serial histologies, but the
destructive nature of histological sampling means exact resam-
pling is impossible. Variable temporal dynamics means that
local fluctuations could work against traditional therapies. An
underlying storage effect would indicate that cell types differ in
their dependence on or sensitivity to specific microenviron-
mental conditions that are fluctuating. Each of them could have
an Achilles’ heel. If one can identify or suggest the trade-off
promoting a storage effect, then a background therapy targeting
quiescent cells could be combined with a standard chemother-
apy and a therapy known to target the specific attributes of the
cancer cell types.
Caveats
As a first step, our focus here has been on how the storage
effect could contribute toward the diversity of cancer cell types
seen in a tumor. This would be in addition to other sources of
intratumor heterogeneity and the many interactions and types
of stromal cells such as fibroblasts, macrophages, and peri-
cytes. Understanding the full community ecology of these
diverse cell types and how the extracellular matrix, for
instance, influences therapy resistance is important.68,69 From
the vantage point of the storage effect, it would be of interest to
know how these other members of the tumor microenviron-
ment influence temporal and spatial fluctuations in key
resources or hazards. If fibroblasts amplify (or dampen) tem-
poral variability, then they may facilitate (or prevent) the coex-
istence of cancer cell types via the storage effect.
Even if the storage effect contributes to 2 coexisting cell
types, identifying them poses challenges. First, each should
have a proliferative and quiescent state, meaning that there
should be 2 identifiably distinct proliferative cell types, 2 dis-
tinct quiescent types, and the correct proliferative types must be
matched with their corresponding quiescent. This is not unlike
the challenge of having 2 yeast species in the same sample
where each yeast species has an active and an encysted form.
Living biopsies or collections of circulating tumor cells may
provide source material for single-cell culturing and the use of
microfluidics to determine the presence of both life-history
stages emerging from the single cell.70,71
Summary
Here, we have described the diversity-promoting mechanism
known as the storage effect and suggested that the conditions
that make the storage effect relevant to ecosystems in nature
also are found in cancer. Research is needed to better identify
and quantify the features of cancer that characterize the storage
effect. These features include population-specific responses to
the environment, which could give differential use of condi-
tions in time by different cancer cell populations; and behaviors
associated with entry into, exit from, and duration of quies-
cence in cancer cells, which could enable buffering of those
populations to environmental fluctuations, allowing them to
evade losses in bad times and realize strong growth in good
times. The possibility that the storage effect is involved in the
clonal ecological heterogeneity and quiescence/dormancy of
cancer cells, both of which pose serious conundrums for cancer
therapies, dictates that more attention should be paid to under-
standing the temporal dimensions of cancer. To do this, both
the data and the models that inform our understanding of cancer
must be expanded to better reveal and account for temporal
variation. If temporal variation in environmental suitability for
growth contributes significantly to population interactions
within the cancer ecosystem, the implications to how we under-
stand and treat cancer would be substantial.
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